Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 2
Insights from POLARIX: How do Novel Perspectives Influence Treatment Outcomes in DLBCL?
An expert discussion on evolving first-line treatment strategies for newly diagnosed diffuse large B-cell lymphoma (DLBCL), incorporating insights from the 2024 NCCN guidelines, unmet needs in 1L therapies, and the impact of POLARIX trial updates on the use of Pola+R-CHP in clinical practice.
Video Player is loading.
Video content above is prompted by the following:
- Discuss treatment strategies for newly diagnosed DLBCL (NCCN guidelines). What factors are most important when selecting treatments for 1L DLBCL?
- What are unmet needs in 1L treatment options in DLBCL.
- With the 2024 NCCN update concerning Pola+R-CHP in DLBCL, how is your standard approach to 1L treatment of DLBCL evolving?
- How does the prolonged follow-up from POLARIX change your view on how and when to use POLA+R-CHP Salles et al. ASH 2024?
Related Content:
